Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors

Cancer Letters

Volumn 311, Issue 1, 2011, Pages 20-28

  Gaur, Shikha ^a   Chen, Linling ^a   Yang, Lixin ^a   Wu, Xiwei ^a   Un, Frank ^a   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

H2AX; Chemotherapeutic drugs; DNA damage; G2 M arrest; MTOR; Topoisomerase II

Indexed keywords

CISPLATIN; DOXORUBICIN; EVEROLIMUS; GYRASE INHIBITOR; HISTONE H2AX; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; S6 KINASE; TEMSIROLIMUS;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CHROMATIN; CHROMATIN DECONDENSATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG SENSITIVITY; HUMAN; HUMAN CELL; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SOLID TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EUKARYOTIC INITIATION FACTORS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; TOPOISOMERASE II INHIBITORS; TOR SERINE-THREONINE KINASES;

EID: 80052142323     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.06.005     Document Type: Article

References (47)

1. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
2. Weiss R.H. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003, 4:425-429.
3. Weiss R.H., Marshall D., Howard L., Corbacho A.M., Cheung A.T., Sawai E.T. Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21(Waf1/Cip1). Cancer Lett 2003, 189:39-48.
4. Rossi F., Labourier E., Forne T., Divita G., Derancourt J., Riou J.F., Antoine E., Cathala G., Brunel C., Tazi J. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 1996, 381:80-82.
5. Hasinoff B.B., Wu X., Krokhin O.V., Ens W., Standing K.G., Nitiss J.L., Sivaram T., Giorgianni A., Yang S., Jiang Y., Yalowich J.C. Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha. Mol Pharmacol 2005, 67:937-947.
6. Hoffmann A., Heck M.M., Bordwell B.J., Rothfield N.F., Earnshaw W.C. Human autoantibody to topoisomerase II. Exp Cell Res 1989, 180:409-418.
7. Hoffmann L., Moller P., Pedersen-Bjergaard J., Waage A., Pedersen M., Hirsch F.R., A report of two cases Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II., literature a review of the Ann Oncol 1995, 6:781-788.
8. Carraway H., Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 2004, 6:219-224.
9. Depowski P.L., Rosenthal S.I., Brien T.P., Stylos S., Johnson R.L., Ross J.S. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Mod Pathol 2000, 13:542-547.
10. Witton C.J. Determining sensitivity to rapamycin and its analogues in breast cancer patients. Breast Cancer Res 2005, 7:41-42.
11. Keith C.T., Schreiber S.L. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 1995, 270:50-51.
12. Khanna K.K., Jackson S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001, 27:247-254.
13. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
14. Guertin D.A., Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol Med 2005, 11:353-361.
15. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
16. Amornphimoltham P., Patel V., Sodhi A., Nikitakis N.G., Sauk J.J., Sausville E.A., Molinolo A.A., Gutkind J.S., rapamycin Mammalian target of a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005, 65:9953-9961.
17. Y.M. Liao, C. Kim, and Y. Yen, Mammalian target of rapamycin and head and neck squamous cell carcinoma, Head Neck Oncol 3 22.
18. C. Clark, S. Shah, L. Herman-Ferdinandez, O. Ekshyyan, F. Abreo, X. Rong, J. McLarty, A. Lurie, E.J. Milligan, and C.O. Nathan, Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients, Laryngoscope 120, 1159-65.
19. Nathan C.O., Amirghahari N., Rong X., Giordano T., Sibley D., Nordberg M., Glass J., Agarwal A., Caldito G. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 2007, 67:2160-2168.
20. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
21. Dowling R.J., Pollak M., Sonenberg N. Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs 2009, 23:77-91.
22. Beuvink I., Boulay A., Fumagalli S., Zilbermann F., Ruetz S., O'Reilly T., Natt F., Hall J., Lane H.A., Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120:747-759.
23. Ferguson P.J., Fisher M.H., Stephenson J., Li D.H., Zhou B.S., Cheng Y.C. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 1988, 48:5956-5964.
24. Gaj C.L., Anyanwutaku I., Chang Y.H., Cheng Y.C. Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line. Biochem Pharmacol 1998, 55:1199-1211.
25. Solly K., Wang X., Xu X., Strulovici B., Zheng W. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2004, 2:363-372.
26. Du L., Frick G.P., Tai L.R., Yoshimura A., Goodman H.M. Interaction of the growth hormone receptor with cytokine-induced Src homology domain 2 protein in rat adipocytes. Endocrinology 2003, 144:868-876.
27. Riccardi C., Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006, 1:1458-1461.
28. Hosoi H., Dilling M.B., Shikata T., Liu L.N., Shu L., Ashmun R.A., Germain G.S., Abraham R.T., Houghton P.J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999, 59:886-894.
29. Huang S., Houghton P.J. Mechanisms of resistance to rapamycins. Drug Resist Updat 2001, 4:378-391.
30. Huang S., Houghton P.J. Resistance to rapamyc. Cancer Metastasis Rev 2001, 20:69-78.
31. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-348.
32. Burma S., Chen B.P., Murphy M., Kurimasa A., Chen D.J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001, 276:42462-42467.
33. Durocher D., Jackson S.P. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?. Curr Opin Cell Biol 2001, 13:225-231.
34. Raleigh J.M., O'Connell M.J. The G(2) DNA damage checkpoint targets both Wee1 and cdc25. J Cell Sci 2000, 113(Pt 10):1727-1736.
35. Boulares A.H., Yakovlev A.G., Ivanova V., Stoica B.A., Wang G., Iyer S., Smulson M., Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. J Biol Chem 1999, 274:22932-22940.
36. Smulson M.E., Pang D., Jung M., Dimtchev A., Chasovskikh S., Spoonde A., Simbulan-Rosenthal C., Rosenthal D., Yakovlev A., Dritschilo A. Irreversible binding of poly(ADP)ribose polymerase cleavage product to DNA ends revealed by atomic force microscopy: possible role in apoptosis. Cancer Res 1998, 58:3495-3498.
37. Wu C., Wangpaichitr M., Feun L., Kuo M.T., Robles C., Lampidis T., Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005, 4:25.
38. Mondesire W.H., Jian W., Zhang H., Ensor J., Hung M.C., Mills G.B., Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004, 10:7031-7042.
39. Grunwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002, 62:6141-6145.
40. Piguet A.C., Semela D., Keogh A., Wilkens L., Stroka D., Stoupis C., St-Pierre M.V., Dufour J.F. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 2008, 49:78-87.
41. Tinari N., Lattanzio R., Natoli C., Cianchetti E., Angelucci D., Ricevuto E., Ficorella C., Marchetti P., Alberti S., Piantelli M., Iacobelli S. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res 2006, 12:1501-1506.
42. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273:5858-5868.
43. Modesti M., Kanaar R. DNA repair: spot(light)s on chromatin. Curr Biol 2001, 11:R229-R232.
44. Guo C.Y., Wang Y., Brautigan D.L., Larner J.M. Histone H1 dephosphorylation is mediated through a radiation-induced signal transduction pathway dependent on ATM. J Biol Chem 1999, 274:18715-18720.
45. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074.
46. Iwamaru A., Kondo Y., Iwado E., Aoki H., Fujiwara K., Yokoyama T., Mills G.B., Kondo S. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 2007, 26:1840-1851.
47. Hait W.N., Jin S., Yang J.M. A matter of life or death (or both): understanding autophagy in cancer. Clin Cancer Res 2006, 12:1961-1965.